Last reviewed · How we verify

NCT07139418

The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy

Recruiting now Last updated 11 March 2026
What this trial tests

trial in Gastric Carcinoma in 400 participants. Currently enrolling.

Timeline
7 October 2025
Primary endpoint
30 August 2027
30 August 2030

Quick facts

Lead sponsorJichao Qin
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment400
Start date7 October 2025
Primary completion30 August 2027
Estimated completion30 August 2030
Sites1 location across China

Conditions studied

Sponsor

Jichao Qin

Who can join

Adults 18 to 85, any sex, with Gastric Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to examine the predictive value of metastatic gastric mesenteries, which contains metastatic lymph node, in 6 gastric mesenteries; and importantly, to further evaluate the relationship between the number of metastatic gastric mesenteries and prognosis in the gastric cancer patients who received D2+complete mesogastric excision (CME).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gastric Carcinoma

Currently open trials in the same condition.

Other Jichao Qin trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07139418.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing